Zydus Lifesciences Acquires US Pharma Firm Assertio Holdings

Zydus Lifesciences plans to acquire Assertio Holdings, a US-based pharmaceutical company, for USD 166.4 million. The acquisition will strengthen Zydus's presence in the US oncology market. The transaction, structured as a tender offer and merger, is expected to complete by the fiscal year 2026-27.

Zydus Lifesciences is set to acquire Assertio Holdings, a US pharmaceutical firm, for USD 166.4 million, approximately Rs 1,590 crore. The acquisition aims to bolster Zydus's US specialty oncology market presence, providing a strategic platform through Assertio's established commercial infrastructure in oncology supportive care.

The transaction is arranged as a tender offer followed by a merger, contingent upon meeting usual closing conditions. Initially, Zydus will launch a tender offer to purchase all outstanding shares of Assertio common stock, representing a strategic move to consolidate its foothold in the US market.

Post tender offer success, Zydus intends to buy all remaining shares not tendered. The acquisition is expected to close in the 2026-27 financial year, expanding Zydus's oncology specialty business globally, aligning with its long-term growth strategy, as noted by Managing Director Sharvil P Patel.